Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Am Soc Hypertens ; 10(11): 857-864.e2, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27697447

RESUMO

We examined baseline data from the Systolic Blood Pressure Intervention Trial (SPRINT) to investigate whether medication adherence, measured by the 8-item Morisky Medication Adherence Scale (MMAS-8), was associated with systolic blood pressure (SBP) and whether MMAS-8 score and number of antihypertensive medications interacted in influencing SBP. A total of 8435 SPRINT participants were included: 21.2% had low adherence (MMAS-8: <6); 40.0% had medium adherence (6 to <8); and 38.8% had high adherence (8). SBP was <140 mm Hg in 54.6%; 140-160 mm Hg in 36.6%; and >160 mm Hg in 8.8%. In multivariable regression, medium vs. low adherence weakly associated with lower SBP (odds ratio: 1.17; confidence interval: 1.04, 1.31). SPRINT eligibility criteria should be considered when interpreting results. Efforts to understand and enhance adherence are crucial to improve population health, and using self-report instruments might be considered for predicting treatment adherence and response in future efficacy trials and for identifying patients for adherence support in clinical practice.


Assuntos
Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Autorrelato , Fatores Etários , Idoso , Anti-Hipertensivos/administração & dosagem , Estudos Transversais , Feminino , Humanos , Masculino , Fatores Sexuais , Sístole
2.
Curr Opin Nephrol Hypertens ; 11(6): 593-6, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12394603

RESUMO

PURPOSE OF REVIEW: The focus of the review is to delineate protocols for catheter removal, catheter replacement and duration of therapy when a catheter-related infection occurs, and to demonstrate possible means of preventing such infections. RECENT FINDINGS: The evidence supporting these views will be discussed in the light of our current practice. SUMMARY: Cuffed tunneled hemodialysis catheters have evolved for wide use as both temporary and semi-permanent hemodialysis access. The primary barriers to long-term catheter use are catheter-related infection and catheter dysfunction. Catheter-related infection has emerged as the primary barrier to long-term catheter use. Under both circumstances, however, catheter replacement or some form of intervention is often needed. Because of this, catheters are often removed and replaced, but the duration of therapy and the timing of replacement of these catheters is not completely clear.


Assuntos
Cateterismo/efeitos adversos , Infecção Hospitalar/terapia , Diálise Renal/efeitos adversos , Bacteriemia/etiologia , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Humanos , Fatores de Risco
3.
Semin Dial ; 16(1): 61-7, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12535303

RESUMO

Dialysis patients who are continually exposed to heparin are at risk for heparin-induced thrombocytopenia (HIT). Heparin-induced antibodies have been reported to occur in 0-12% of hemodialysis (HD) patients. The diagnosis or suspicion of HIT in this patient population requires careful confirmation of the diagnosis and substitution of heparin with an alternate anticoagulant for dialysis. Alternate agents such as the direct thrombin inhibitors (hirudin and argatroban) are available, but careful dosing and monitoring of the anticoagulant effect are required. Despite careful dosing, hemorrhagic complications have occurred with these agents. Unfortunately there are limited options for treatment of hemorrhagic complications and no specific antidotes are available for the direct thrombin inhibitors. In this report the currently available alternatives to heparin for dialysis, including dosing and monitoring recommendations, are reviewed.


Assuntos
Anticoagulantes/efeitos adversos , Heparina/efeitos adversos , Hirudinas/análogos & derivados , Trombina/antagonistas & inibidores , Trombocitopenia/induzido quimicamente , Anticoagulantes/administração & dosagem , Arginina/análogos & derivados , Ensaios Clínicos como Assunto , Fibrinolíticos/uso terapêutico , Heparina/administração & dosagem , Heparinoides/uso terapêutico , Terapia com Hirudina/métodos , Humanos , Fragmentos de Peptídeos/uso terapêutico , Ácidos Pipecólicos/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Diálise Renal/métodos , Sulfonamidas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA